Relexxii (Methylphenidate HCl) Patent Expiration, LOE Window & CMS Spending

Relexxii (Methylphenidate HCl) by Osmotica Us: FDA Orange Book LOE 2037-02-03, 13 AB generics, $475K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorOsmotica Us
FDA Application & PathwayN216117 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2037-02-03
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors13
2024 CMS Total Public Spend$475K
2024 Medicare Part D Spend$39K
2024 Medicaid Spend$436K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel